tradingkey.logo

Sonnet Biotherapeutics Holdings Inc

SONN
1.260USD
0.000
Close 12/24, 13:00ETQuotes delayed by 15 min
4.20MMarket Cap
LossP/E TTM

Sonnet Biotherapeutics Holdings Inc

1.260
0.000
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison

TradingKey Stock Score of Sonnet Biotherapeutics Holdings Inc

Currency: USD Updated: 2025-12-02

Key Insights

Sonnet Biotherapeutics Holdings Inc's fundamentals are relatively very healthy, Its valuation is considered fairly valued, Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at max_target_price.Despite a very weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Sonnet Biotherapeutics Holdings Inc's Score

Industry at a Glance

Industry Ranking
174 / 404
Overall Ranking
304 / 4582
Industry
Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Analyst Rating

Based on 1 analysts
Buy
Current Rating
20.000
Target Price
+1487.30%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Sonnet Biotherapeutics Holdings Inc Highlights

StrengthsRisks
Sonnet BioTherapeutics Holdings, Inc. is a clinical-stage, oncology-focused biotechnology company with a proprietary platform for biologic medicines of single-or bifunctional action. The Fully Human Albumin Binding (FHAB), a technology which utilizes a fully human single chain antibody fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its FHAB is designed to specifically target tumor and lymphatic tissue. The Company's lead program, SON-1010, or IL-12-FHAB, is in development for the treatment of solid tumors and ovarian cancer. SON-1010 is being evaluated in an ongoing Phase 1/2a study, in combination with atezolizumab (Tecentriq) for the treatment of platinum-resistant ovarian cancer (PROC). The Company is also evaluating its second program, SON-1210, an IL12-FHAB-IL15 for solid tumor. Its SON-080 program is a low dose of rhIL-6 in development for Chemotherapy-Induced Peripheral Neuropathy (CIPN) and Diabetic Peripheral Neuropathy (DPN).
Growing
The company is in a growing phase, with the latest annual income totaling USD 18.63K.
Fairly Valued
The company’s latest PE is -0.18, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 348.20K shares, decreasing 56.05% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 96.38K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.75.

Financial Health

Currency: USD Updated: 2025-12-02

The current financial score of Sonnet Biotherapeutics Holdings Inc is 6.70, ranking industry_rank/industry_total in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low.

Score

Industry at a Glance

Previous score
6.70
Change
0

Financials

10.00

Key Metrics

Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.

Quality of Earnings

7.05

Operational Efficiency

2.67

Growth Potential

6.78

Shareholder Returns

7.03

Sonnet Biotherapeutics Holdings Inc's Company Valuation

Currency: USD Updated: 2025-12-02

The current valuation score of Sonnet Biotherapeutics Holdings Inc is 7.66, ranking industry_rank/industry_total in the Biotechnology & Medical Research industry. Its current P/E ratio is -0.18, which is -491.07% below the recent high of 0.72 and -4501.41% above the recent low of -8.50.

Score

Industry at a Glance

Previous score
7.66
Change
0

Valuation Dimensions

P/E
P/B
P/S
P/CF
Industry Ranking 174/404
Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2025-12-02

The current earnings forecast score of Sonnet Biotherapeutics Holdings Inc is 8.00, ranking industry_rank/industry_total in the Biotechnology & Medical Research industry. The average price target for Sonnet Biotherapeutics Holdings Inc is 20.00, with a high of 20.00 and a low of 20.00.

Score

Industry at a Glance

Previous score
8.00
Change
0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 1 analysts
Buy
Current Rating
20.000
Target Price
+1487.30%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

534
Total
6
Median
6
Average
Company name
Ratings
Analysts
Sonnet Biotherapeutics Holdings Inc
SONN
1
CRISPR Therapeutics AG
CRSP
30
argenx SE
ARGX
25
Intellia Therapeutics Inc
NTLA
25
IQVIA Holdings Inc
IQV
25
Ionis Pharmaceuticals Inc
IONS
24
1
2
3
...
107

Financial Forecasting

EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-12-02

The current price momentum score of Sonnet Biotherapeutics Holdings Inc is 4.97, ranking industry_rank/industry_total in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 4.39 and the support level at -0.30, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score
4.09
Change
0.88

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators

The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators
Sell(3)
Neutral(0)
Buy(0)
Indicators
Value
Direction
MACD(12,26,9)
-0.628
Sell
RSI(14)
28.160
Sell
STOCH(KDJ)(9,3,3)
4.039
Oversold
ATR(14)
0.932
High Vlolatility
CCI(14)
-265.524
Oversold
Williams %R
100.000
Oversold
TRIX(12,20)
-0.604
Sell
StochRSI(14)
0.000
Oversold
Moving Average
Sell(6)
Neutral(0)
Buy(0)
Indicators
Value
Direction
MA5
3.279
Sell
MA10
3.960
Sell
MA20
4.347
Sell
MA50
4.616
Sell
MA100
4.488
Sell
MA200
3.012
Sell

Institutional Confidence

Currency: USD Updated: 2025-12-02

The latest institutional shareholding proportion is 4.92%, representing a quarter-over-quarter increase of 31.97%. The largest institutional shareholder is The Vanguard, holding a total of 96.38K shares, representing 1.36% of shares outstanding, with 2169.50% increase in holdings.

Score

Industry at a Glance

Previous score
3.00
Change
0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name
Shares Held
Chg %
Republic Digital Opportunistic Digital Assets Master Fund Ltd
260.00K
--
The Vanguard Group, Inc.
Star Investors
28.10K
--
Kenney (Richard T)
1.37K
--
Geode Capital Management, L.L.C.
24.89K
+0.35%
BIT Capital GmbH
428.79K
+120.28%
1
2

Risk Assessment

Currency: USD Updated: 2025-12-02

The current risk assessment score of Sonnet Biotherapeutics Holdings Inc is 1.26, ranking industry_rank/industry_total in the Biotechnology & Medical Research industry. The company's beta value is 1.52. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.

Score

Industry at a Glance

Previous score
1.26
Change
0
Beta vs S&P 500 index
1.60
VaR
+11.11%
240-Day Maximum Drawdown
+87.10%
240-Day Volatility
+206.29%

Return

Best Daily Return
60 days
+48.99%
120 days
+242.98%
5 years
+242.98%
Worst Daily Return
60 days
-59.35%
120 days
-59.35%
5 years
-59.35%
Sharpe Ratio
60 days
-0.05
120 days
+1.24
5 years
-0.22

Risk Assessment

Maximum Drawdown
240 days
+87.10%
3 years
+99.48%
5 years
+99.98%
Return-to-Drawdown Ratio
240 days
-0.35
3 years
-0.33
5 years
-0.20
Skewness
240 days
+6.78
3 years
+8.29
5 years
+8.14

Volatility

Realised Volatility
240 days
+206.29%
5 years
+170.11%
Standardised True Range
240 days
+38.83%
5 years
+4612.14%
Downside Risk-Adjusted Return
120 days
+398.69%
240 days
+398.69%
Maximum Daily Upside Volatility
60 days
+202.62%
Maximum Daily Downside Volatility
60 days
+157.33%

Liquidity

Average Turnover Rate
60 days
+114.67%
120 days
+58.45%
5 years
--
Turnover Deviation
20 days
-74.94%
60 days
+43.75%
120 days
-26.73%

Peer Comparison

Biotechnology & Medical Research
Sonnet Biotherapeutics Holdings Inc
Sonnet Biotherapeutics Holdings Inc
SONN
5.84 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Amicus Therapeutics Inc
Amicus Therapeutics Inc
FOLD
8.82 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
IQVIA Holdings Inc
IQVIA Holdings Inc
IQV
8.67 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Dynavax Technologies Corp
Dynavax Technologies Corp
DVAX
8.56 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
BioCryst Pharmaceuticals Inc
BioCryst Pharmaceuticals Inc
BCRX
8.50 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Krystal Biotech Inc
Krystal Biotech Inc
KRYS
8.46 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more

FAQs

How does TradingKey generate the Stock Score of Sonnet Biotherapeutics Holdings Inc?

The TradingKey Stock Score provides a comprehensive assessment of Sonnet Biotherapeutics Holdings Inc based on 34 indicators derived from over 100 underlying data points.
These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of Sonnet Biotherapeutics Holdings Inc’s performance and outlook.

How do we generate the financial health score of Sonnet Biotherapeutics Holdings Inc?

To generate the financial health score of Sonnet Biotherapeutics Holdings Inc, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns.
By integrating these comprehensive data, the financial health score not only reflects Sonnet Biotherapeutics Holdings Inc's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of Sonnet Biotherapeutics Holdings Inc.

How do we generate the company valuation score of Sonnet Biotherapeutics Holdings Inc?

To generate the company valuation score of Sonnet Biotherapeutics Holdings Inc, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare Sonnet Biotherapeutics Holdings Inc’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value.
By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of Sonnet Biotherapeutics Holdings Inc’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of Sonnet Biotherapeutics Holdings Inc.

How do we generate the earnings forecast score of Sonnet Biotherapeutics Holdings Inc?

To calculate the earnings forecast score of Sonnet Biotherapeutics Holdings Inc, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:
Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.
Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.
By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.
Comparing these indicators against peers provides context for the stock’s performance and helps anchor more realistic expectations.
These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on Sonnet Biotherapeutics Holdings Inc’s future.

How do we generate the price momentum score of Sonnet Biotherapeutics Holdings Inc?

When generating the price momentum score for Sonnet Biotherapeutics Holdings Inc, we examine momentum indicators including support and resistance levels as well as volume metrics.
Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.
This comprehensive approach can reflect market sentiment and enable rational forecasts of Sonnet Biotherapeutics Holdings Inc’s prices. A higher score indicates a more stable short-term price trend for Sonnet Biotherapeutics Holdings Inc.

How do we generate the institutional confidence score of Sonnet Biotherapeutics Holdings Inc?

To generate the institutional confidence score of Sonnet Biotherapeutics Holdings Inc, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about Sonnet Biotherapeutics Holdings Inc’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of Sonnet Biotherapeutics Holdings Inc.

How do we generate the risk management score of Sonnet Biotherapeutics Holdings Inc?

To assess the risk management score of Sonnet Biotherapeutics Holdings Inc, we examine multiple key indicators related to returns, risk, volatility, and liquidity.
The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.
These indicators together provide a multi-dimensional understanding of Sonnet Biotherapeutics Holdings Inc’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of Sonnet Biotherapeutics Holdings Inc.
KeyAI